Combivir And Maraviroc In Antiretroviral Naive Subjects In Russia
A Multicenter, Open Label Study Of Maraviroc, Zidovudine And Lamivudine Twice Daily For The Treatment Of Antiretroviral Naïve HIV-Infected Patients With R5 HIV-1 In Russia
Visão geral do estudo
Status
Status
Condições
Condições
Intervenção / Tratamento
Intervenção / Tratamento
Tipo de estudo
Tipo de estudo
Inscrição (Real)
Inscrição
Estágio
Estágio
- Fase 4
Contactos e Locais
Locais de estudo
-
-
-
Krasnoyarsk, Federação Russa, 660049
- Regional Center on AIDS and Infectious Diseases Prophylaxis and Control
-
Moscow, Federação Russa, 105275
- Federal scientific and methodological center on AIDS prophylaxis and control
-
Moscow, Federação Russa, 129110
- Moscow regional center on AIDS and infectious diseases prophylaxis and control
-
Nizhnij Novgorod, Federação Russa, 603005
- Regional Center on AIDS and Infectious Diseases Prophylaxis and Control
-
Saint-Petersburg, Federação Russa, 190103
- Saint-Petersburg Center on AIDS and Infectious Diseases Prophylaxis and Control
-
Saint-Petersburg, Federação Russa, 196645
- Federal State Institution Republican clinical infectious hospital of Roszdrav
-
Smolensk, Federação Russa, 214006
- Smolensk Center on AIDS and infectious diseases prophylaxis and control
-
Volgograd, Federação Russa, 400040
- Volgograd Regional Center on AIDS and Infectious Diseases Prophylaxis and Control
-
-
Critérios de participação
Critérios de elegibilidade
Critérios de elegibilidade
Idades elegíveis para estudo
Aceita Voluntários Saudáveis
Gêneros Elegíveis para o Estudo
Descrição
Inclusion Criteria:
- Over 18 years of age.
- R5 HIV infection on screening tropism test.
- Viral load >1,000 copies/mL.
- Never previously treated with anti-HIV medicines.
Exclusion Criteria:
- Previously treated with anti-HIV medicines.
- Hepatitis B co-infection.
Plano de estudo
Como o estudo é projetado?
Detalhes do projeto
- Finalidade Principal: Tratamento
- Alocação: Não randomizado
- Modelo Intervencional: Atribuição de grupo único
- Mascaramento: Nenhum (rótulo aberto)
Número de braços
Armas e Intervenções
Grupo de Participantes / BraçoGrupo de Participantes / Braço |
Intervenção / TratamentoIntervenção / Tratamento |
|---|---|
|
Experimental: Treatment
Single arm study of combivir and maraviroc for 48 weeks
|
Combivir one tablet BD with maraviroc 300mg BD for 48 weeks
Outros nomes:
|
O que o estudo está medindo?
Medidas de resultados primários
Medidas de resultados primários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Percentage of Participants With Plasma Human Immuno Deficiency Virus-1 Ribonucleic Acid (HIV-1 RNA) Load <50 Copies/Milliliter (mL) at 48 Weeks.
Prazo: 48 weeks
|
Participants' responder status at Week 48 was assessed according to Missing, discontinuation= Failure (MDF) algorithm.
This algorithm treats all participants with HIV 1 RNA data missing at the time of interest or discontinuation of study drug as failures or non responders.
|
48 weeks
|
Medidas de resultados secundários
Medidas de resultados secundários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Virologic Response: Percentage of Participants With Plasma HIV-1 RNA Load <50 Copies/mL at Post-baseline Visits.
Prazo: Baseline, Week 4, Week 8, Week 12, Week 20, Week 24, Week 36 and Week 48
|
Participants' responder status at Week 48 was assessed according to MDF algorithm.
This algorithm treats all participants with HIV 1 RNA data missing at the time of interest or discontinuation of study drug as failures or non responders.
|
Baseline, Week 4, Week 8, Week 12, Week 20, Week 24, Week 36 and Week 48
|
|
Virologic Response: Percentage of Participants With Plasma HIV-1 RNA Load < 400 Copies/mL at Post-baseline Visits.
Prazo: Baseline, Week 4, Week 8, Week 12, Week 20, Week 24, Week 36 and Week 48
|
Participants' responder status at Week 48 was assessed according to MDF algorithm.
This algorithm treats all participants with HIV 1 RNA data missing at the time of interest or discontinuation of study drug as failures or non responders.
|
Baseline, Week 4, Week 8, Week 12, Week 20, Week 24, Week 36 and Week 48
|
|
Virologic Response: Rate of Virologic Failure at Week 48.
Prazo: 48 weeks
|
Virologic failure defined as: failure to achieve a reduction from baseline in HIV 1 RNA ≥ 0.5 log10 copies /mL by the second viral load determination (unless viral load was below the lower limit level of quantification [LLOQ]); or a ≥ 0.5 log10 increase from nadir in HIV 1 RNA after achieving a HIV 1 RNA reduction from BL >0.5 log10 copies/mL; or a HIV 1 RNA level of >1000 copies/mL after having achieved a HIV 1 RNA level below LLOQ.
Participants with Time to loss of virologic response (defined by level of <50 copies/mL) failure were classified as rebounders or non-responders.
|
48 weeks
|
|
Immunological Response at Week 48: Absolute Change From Baseline in Absolute Cluster of Differentiation 4 (CD4)
Prazo: Week 48
|
Immunological Response was summarized using absolute change from Baseline to Week 48 in absolute CD4+ cell count
|
Week 48
|
|
Immunological Response at Week 48: Percentage Change From Baseline in Absolute Cluster of Differentiation 4 (CD4)
Prazo: Week 48
|
Immunological Response was summarized using percentage change from Baseline to Week 48 in absolute CD4+ cell count
|
Week 48
|
|
Immunological Response at Week 48: Absolute Change From Baseline in Absolute Cluster of Differentiation 8 (CD8)
Prazo: Week 48
|
Immunological Response was summarized using absolute change from Baseline to Week 48 in absolute CD8+ cell count.
|
Week 48
|
|
Immunological Response at Week 48: Percentage Change From Baseline in Absolute Cluster of Differentiation 8 (CD8)
Prazo: Week 48
|
Immunological Response was summarized using percentage change from Baseline to Week 48 in absolute CD8+ cell count.
|
Week 48
|
|
Immunological Response at Week 48: Change From Baseline in Absolute Cluster of Differentiation 4 (CD4)/ Cluster of Differentiation 8 (CD8) Ratio.
Prazo: Week 48
|
Immunological Response was summarized using absolute change from Baseline to Week 48 in absolute CD4+/ CD8+ ratio.
|
Week 48
|
|
Number of Participants With Genotypic Resistance.
Prazo: Screening to Week 48 or Time of treatment Failure
|
The viral genotypes were captured at Baseline and at treatment failure or Early termination and any resistance-associated mutations summarized descriptively at Week 48 for the Nucleotide reverse transcriptase inhibitors (NRTIs), and non-NRTIs (NNRTIs)drug classes.
|
Screening to Week 48 or Time of treatment Failure
|
|
Number of Participants With HIV-1 RNA Tropism Status Using Genotyping Assay at Screening and at the Time of Virologic Failure.
Prazo: Screening to Week 48 or Time of treatment Failure
|
Change in tropism were summarized at the time of treatment failure or Early Termination (note: this was performed for participants with viral load > 400 copies/mL only).
|
Screening to Week 48 or Time of treatment Failure
|
Colaboradores e Investigadores
Patrocinador
Patrocinador
Colaboradores
Colaboradores
Publicações e links úteis
Datas de registro do estudo
Datas Principais do Estudo
Início do estudo
Início do estudo
Conclusão Primária (Real)
Conclusão Primária
Conclusão do estudo (Real)
Conclusão do estudo
Datas de inscrição no estudo
Enviado pela primeira vez
Enviado pela primeira vez
Enviado pela primeira vez que atendeu aos critérios de CQ
Enviado pela primeira vez que atendeu aos critérios de CQ
Primeira postagem (Estimativa)
Primeira postagem
Atualizações de registro de estudo
Última Atualização Postada (Estimativa)
Última Atualização Postada
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última verificação
Última verificação
Mais Informações
Termos relacionados a este estudo
Palavras-chave
Termos MeSH relevantes adicionais
Outros números de identificação do estudo
Outros números de identificação do estudo
- A4001101
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .